Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01413191 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Ciliary Body and Choroid Melanoma, Medium/Large Size
Ciliary Body and Choroid Melanoma, Small Size
Iris Melanoma
Metastatic Intraocular Melanoma
Recurrent Intraocular Melanoma
Stage IV Intraocular Melanoma

Interventions

BIOLOGICAL: Cixutumumab
OTHER: Laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)